Elevated expression of NAD(P)H:Quinone Oxidoreductase 1 (NQO1) is frequent in pancreatic cancer, allowing for tumor-selective targeting, and NQO1-bioactivatable compounds have been shown to be highly effective against lung and pancreatic cancer3–6. The gene discussed is NQO1; the disease is familial pancreatic carcinoma.